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In the tumor dormant state, small numbers of tumor cells persist in the host without 
outgrowth to overt neoplasia. The cancer literature contains numerous reports describing 
recurrence of solid tumors and leukemias years after apparent successful treatment of the 
primary neoplasia (1). These reports suggest that residual tumor cells can persist in a 
dormant state during the prolonged clinical remission. Few experimental models have 
been  developed to  study  the  tumor  dormant  state.  In  this  laboratory we  have  been 
investigating a  murine model in which the rapidly fatal Friend virus erythroleukemia 
can be suppressed to a  dormant state by treatment with statolon, an extract of myco- 
phage-infected Penicillium  stoloniferum  cultures  (2-4),  or  the  double-stranded  RNA 
extracted from statolon (5).  This report describes our continuing analysis of host mecha- 
nisms involved in maintenance of Friend leukemia virus (FLV)  ~ in a  dormant state. 
Infection of DBA/2 mice with  FLV causes  a  depression in humoral  (6)  and  cellular 
immunity  (7)  and  macrophage  functions  (8)  followed  by  the  development  of a  fatal 
erythroleukemia (2). Treatment of FLV-infected mice with statolon abrogates the depres- 
sion of humoral immunity and macrophage functions (6, 8). Between 50 and 70% of these 
mice maintain immunocompetence  and survive, suppressing the erythroleukemia to a 
dormant  state,  which  lasts  for  the  normal  lifespan  of most  of these  mice  (2-4,  9). 
However, late in life, some of  these mice develop erythroleukemia from which FLV can be 
isolated (2,  3).  Mice with dormant FLV infections contain antibodies that complex FLV 
virion polypeptides and  are cytotoxic for FLV-transformed cells, and these  antibodies 
appear to be crucial for leukemosuppression and maintenance of the virus in a dormant 
state  (9-11).  Serum from mice with dormant l%V infections is referred to as dormant 
FLV-immune serum (FVIS). 
The precise mechanism by which FLV antibodies suppress FLV erythroleukemia and 
maintain the virus in a dormant state is not known. DBA/2 mice are deficient in the fifth 
component of complement (C5) (12) which is required for antibody-mediated complement- 
dependent immune cytolysis (13).  Carlson and Terres demonstrated antibody-dependent 
killing of syngeneic  lymphomas  by  the  DBA/2  mouse  in  vivo  (14).  The  mechanism 
involved in this destruction of the lymphomas was most likely antibody-dependent cell- 
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mediated cytotoxicity (ADCC); however, extensive attempts in our laboratory to demon- 
strate ADCC in vitro using FLV erythroleukemic cells as targets and FVIS have been 
negative (unpublished results). A  third type of antibody-tumor cell interaction is anti- 
genic modulation. We therefore explored the possibility that FVIS might maintain FLV 
in a  dormant state through antigenic modulation. 
Antigenic modulation is the phenotypic suppression of a  cell surface antigen during 
exposure to specific antibody in the absence of complement (C); withdrawal of antibody 
from  the  environment  of modulated  cells results  in  the  re-expression of cell  surface 
antigen  (15,  16).  Boyse  et  al.  (17)  demonstrated  that  antigenic  modulation  was  the 
mechanism  involved in  the  escape  and outgrowth  of thymus-leukemia  (TL)  antigen- 
positive thymomas in TL antigen-immune mice. Modulation of TL antigen expression on 
the surface of leukemic cells was also observed after in vitro exposure to specific antibody 
(15,  18).  In vivo antigenic modulation has  also been described for the Gross virus cell 
surface antigen (GCSA) in mice (19), Gross leukemia virus expression in rats (20), fetal 
antigens on Rauscher leukemia virus-induced C57/BL6 lymphomas (21),  and SV-40 virus 
antigen expression in transformed hamster fibroblasts (22).  Antigenic modulation was 
also observed in vitro with human  melanoma cell surface  antigens  (23),  Epstein-Barr 
virus (EBV) antigen expression in Burkitt lymphoma cells (23, 24), murine H-2 antigens 
(16,  25),  murine mammary tumor virus (MuMTV)  antigens (26),  membrane-associated 
immunoglobulins of lymphoid cells (16, 27-29), and measles virus antigens in persistently 
and acutely infected HeLa cells (30). 
The interaction of antibody with cell surface antigen may result in antigen-antibody 
complexes which redistribute on the cell surface into patches and caps (31, 32), and this 
capping phenomenon has been associated with antigenic modulation (31).  Antigen cap- 
ping and antigenic modulation are dependent upon active cellular metabolism (15, 25, 32, 
33), but each event can occur independently (34-36). 
In  order  to  determine  whether  modulation  of FLV  antigens  is  involved  in 
maintenance  of dormant  FLV infection, an in vitro model was developed. This 
communication  reports that FLV erythroleukemic  cells cultured in FVIS, in the 
absence  of C  are  markedly  diminished  in  their  susceptibility to  FLV-specific 
immune  cytolysis. Immunofluorescent  studies demonstrate  a  temporal  correla- 
tion  between  capping  and  modulation  of FLV  antigens.  Finally,  evidence  for 
inhibition  of the expression of the  FLV  genome  in  modulated  Friend  erythro- 
leukemic cells is presented. 
Materials  and  Methods 
Cells.  Clone 745 of Friend erythroleukemia cells (FLC-745) were obtained from the Genetic 
Mutant Cell Repository, Institute for Medical Research, Camden, N. J., which has designated this 
clone GM86. The cell line was derived from solid leukemic tumors passaged in DBA/2 mice (37). 
The cells were maintained in suspension culture in 75 cm  2 plastic tissue culture flasks, and 
transferred twice weekly at a final concentration of 10  ~ cells/ml of culture medium, consisting of 
RPMI 1640 (pH 7.0) with 20% heat-inactivated fetal bovine serum and 100 tLg/ml streptomycin, 100 
U/ml penicillin, 100 t~g/ml gentamycin, and 2 mM glutamine. All cultures were incubated at 37°C 
in a humidified chamber containing a 5% CO2 atmosphere. 
Mouse Serum.  Mouse serum was obtained from ether anesthetized mice, bled from the right 
axilla. The blood was pooled and allowed to clot for 2-4, h  at 4°C. Serum was collected after 
centrifugation at 300 g for 10 rain, and stored at -70°C. Serum was heat inactivated by incubation 
in a 56°C water bath for 30 rain. Heat-inactivated serum was diluted in culture medium to obtain a 
final 5% concentration for experimental cell culture medium, and filtered through a  0.45  t~m 
Millipore filter (Millipore Filter Corp., Bedford, Mass.). Normal mouse serum (NMS) was ob- 
tained from 6- to 8-wk-old female DBA/2 mice (The Jackson Laboratory, Bar Harbor, Maine). 
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leukemia-producing doses of FLV,  treated  with chlorite-oxidized oxyamylose and  statolon as 
previously described (38). 35 days after FLV infection, those mice displaying no gross evidence of 
erythroleukemia were designated as having dormant FLV infections, and were bled for their sera. 
FVIS is cytotoxic for FLV-transformed cells in the presence of guinea pig C (9-11).  Heat inactiva- 
tion does not alter the C-dependent cytotoxic titer of FVIS  (data not shown). Anti-DBA/2 C- 
dependent cytotoxic serum was obtained from C57BL/6 mice (The Jackson Laboratory), immu- 
nized with DBA/2 spleen cells as described by Davies (39). 
Experimental Cell Culture System.  For in vitro cell culture experiments, 1.5  x  l0  s cells were 
suspended in 3 ml of  culture medium containing 5% heat-inactivated mouse serum in 16 x  125 mm 
plastic tissue culture tubes (Falcon Plastics, Div. of BioQuest, Oxnard, Calif.). At 24-h intervals, 
a  sample  was  removed and  cell  number determined by  hemocytometer counts  and  viability 
determined by  erythrocin B  dye exclusion. Except where indicated,  cells were maintained in 
logarithmic growth phase by redilution every 24  h  to 5  ×  105  cells/ml in a  final 3-ml culture 
volume, using fresh medium containing 5% heat-inactivated mouse serum. Under these culture 
conditions, FLC-745 cells have a population doubling time of 18-20  h. 
Assay for Cell Susceptibility to Immune Cytolysis.  Cell susceptibility to immune cytolysis was 
measured by a  modified 5~Cr-release method originally described by Wigzell (40).  FLC-745 cells 
were centrifuged at 300 g  for 10 rain, and resuspended  to a concentration of 3 ×  106 viable cells/ml 
in the experimental culture medium in which they were grown. The use of the experimental 
culture medium assured that the cells were maintained in the appropriate experimental environ- 
ments during the 51Cr-labeling  period.  The cells  were incubated with 120/~Ci of  5~Cr [(Na51CrO~); 
New England Nuclear, Boston, Mass.] per ml of  cells  for 90 rain  at 37°C. The labeled cells  were 
centrifuged through a 0.5 ml heat-inactivated fetal  bovine serum underlay, then washed twic  e at 
4°C in assay medium  consisting of RPMI  1640 supplemented with 10% heat-inactivated fetal 
bovine serum, and resuspended in fresh assay medium at a concentration of 2.5 x 105 cells/ml. 
This suspension was maintained at 4°C and used immediately for the assay. 
The assay was performed in ISFB-96 Linbro plastic  microcytotoxicity  plates (Linbro Chemical 
Co.,  New Haven, Conn.) containing 2.5 x 104  sICr-labeled  cells  in  medium with  5% (vol/vol)  guinea 
pig C (Baltimore Biological  Laboratories, Cockeysville, Md.), and 5% FVIS cytotoxic  serum in a 
final vol of 200 ~I/well.  This concentration of FVIS produces maximum  lysis  of FLC-745 target 
cells  in  the  presence of  C. The plates  were incubated at  37°C for  90 rain,  then  centrifuged  for  10  rain 
at 300 g in an IEC Model No. 442 flat-bottomed centrifuge rotor (Damon/IEC  Div., Needham 
Heights, Mass.), and counted in a Searle gamma  counter (Amersham/Searle  Corp., Arlington 
Heights, Ill.).  Spontaneous release  control  wells  contained 2.5 x 104  target  cells  in  200 ~tl  of  assay 
medium. To test  for cell  susceptibility  to lysis  by C alone, target  cells  were mixed with assay 
medium  containing  a final 5% (vol/vol)  guinea pig C. Maximum  release was determined by 
hypotonic water lysis  of  2.5 x 104 target  cells  diluted 1:20  in distilled  water. All assays were done 
in duplicate.  Percent specific  release was calculated as follows: 
Supernate cpm of  experimental groups - supernate cpm of  spontaneous release x 100%. 
Supernate cpm of maximal release -  supernate cpm of spontaneous release 
MembraneImmunofluorescenceAssayforFVISGammaGlobulinandFLVAntigens.  In order 
to detect the presence of FVIS 7S  gamma globulin bound to the cell surface,  experimentally 
cultured FLC-745 cells were washed in phosphate-buffered saline (PBS), pH 7.4,  at 4°C,  centri- 
fuged at 300 g  for 10 min, and resuspended to a final concentration of 2.5  x  106 cells/ml in a  1:4 
dilution of fiuorescein-conjugated goat anti-mouse 7S  gamma globulin (fl-GAMg; Hyland Div., 
Travenol Laboratories, Inc., Costa Mesa, Calif.) in PBS. The cells were maintained in suspension 
at 4°C for 20 rain with occasional agitation, then washed three times in PBS by centrifugation, 
resuspended, and examined under an American Optical Vertical Fluorescence Microscope (Ameri- 
can Optical Corp., Scientific Instrument Div., Buffalo, N.  Y.). The labeled cell suspension was 
viewed with a tungsten light source or an ultraviolet light source, obtained from an Osram HBO 
50W mercury vapor lamp, in combination with a  BG-12 exciter filter and an OG-1  barrier filter. 
100-125  viable  cells  per  slide  were  counted and  examined for fluorescence and  fluorescence 
distribution. The criterion used to determine the viability of fluorescent-stained cells was de- 
scribed by  MSller  (41).  Fluorescence distribution was  categorized as  rim,  patch,  and  cap  as 
previously described by others (31, 32). In order to detect the expression of  FLV antigens at the cell 
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rain at 4°C,  then washed, centrifuged, stained with fl-GAMg, and observed for fluorescence as 
described above. 
Results 
Modulation of FL  V Cell Surface Antigens during Culture of Friend Erythro- 
leukemic  Cells  in  Dormant FVIS.  FLC-745  cells  were  cultured  in  medium 
containing FVIS to determine the effect of antibodies directed against FLV cell 
surface antigens on cell growth,  viability, and susceptibility to FVIS-mediated 
C-dependent  cytolysis. Two cultures  of FLC-745 cells were initiated  with me- 
dium  containing  either  5%  heat-inactivated  NMS  or FVIS.  After 24 h,  each 
culture was divided into two subcultures. One subculture was diluted with fresh 
medium containing  FVIS or NMS to maintain  the cells in logarithmic growth 
phase.  Cells in the other subculture were not diluted, but allowed to grow into 
the stationary phase.  At 24 and 48 h,  the total cell number and viability was 
determined, and the cells were labeled with 51Cr, and tested for their susceptibil- 
ity to cytolysis by FVIS in the presence of C or by C alone. 
Table I shows that during the 48-h incubation period, there was, in both the 
logarithmic and stationary growth phase cultures, no difference in growth and 
viability of cells cultured in FVIS or NMS. However, FLC-745 cells cultured in 
FVIS for 48 h in the logarithmic growth phase were significantly more resistant 
to cytolysis by FVIS than  were cells cultured  logarithmically  in  NMS.  Cells 
cultured in FVIS in the stationary growth phase developed resistance to cytoly- 
sis by FVIS, but to a  lesser degree than did cells cultured in the logarithmic 
growth phase. Of the four experimental cultures, cells in the logarithmic growth 
phase grown in NMS were most susceptible to cytolysis by FVIS and cells in the 
logarithmic  phase  grown  in  FVIS were least  susceptible.  The  cells  from the 
various cultures were not significantly lysed by the addition of C alone. The data 
indicate that FVIS modulates FLV antigen expression on erythroleukemic cells 
resulting  in  a  loss of susceptibility to  cytolysis by FVIS.  The  degree  of this 
modulation is affected by the growth phase of the cells in culture. Since modula- 
tion of FLV antigen expression on FLC-745 cells cultured in FVIS was optimal 
when the cells were in the logarithmic growth phase,  these culture conditions 
were employed for all subsequent experiments. 
Kinetics of Modulation of FLV Cell Surface Antigens on FLC-745 Cells and 
Reversal of Modulation.  To determine the kinetics of antigenic  modulation, 
FLC-745 cells were cultured in the logarithmic growth phase for 96 h  in media 
containing FVIS and examined at 24-h intervals for cell growth, viability, and 
susceptibility  to  cytolysis  by  FVIS  in  the  presence  of C  or  by  C  alone.  To 
determine  whether  antigenic  modulation  was  reversible,  FLC-745 cells were 
cultured in FVIS for 48 h, washed free of FVIS, and cultured for an additional 48 
h in fresh media with either NMS or no mouse serum. Unmodulated cells grown 
in media with either NMS or media without mouse serum were treated identi- 
cally and served as controls. 
Fig. 1 shows that FLC-745 cells cultured in medium containing FVIS for 24 h 
became relatively resistant to cytolysis by FVIS and continued to be resistant 
throughout  the  96-h  culture  period  compared  to  FLC-745  cells  cultured  in 
medium devoid of FVIS.  FLC-745 cells that  were modulated  after culture  in 
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TABLE  I 
Growth,  Viability,  and Susceptibility  to FLV-Immune Cytolysis of FLC-745 Cells 
Cultured in Either NMS or Dormant FVIS 
Time in culture* 
% Increase ins  % Viable cells  % 5'Cr release¶ 
cell no. 
NMS§  FVIStl  NMS  FVIS  NMS  FVIS 
h 
24  148  136  92  91  ND**  ND 
48 (logarithmic)  160  158  95  93  45.3  _+ 1.0  8.5  _+ 0.1 
48 (stationary)  52  58  87  89  24.4  +_ 0.4  16.6  _+ 0.6 
* All cell cultures were initiated with 5  ×  105 cells/ml of culture volume. At 24 h, the cultures 
were divided into logarithmic and stationary growth phase subcultures as indicated. Subcul- 
tures  were  maintained in  logarithmic  growth  phase  by dilution in  fresh  medium  at  24  h. 
Stationary growth phase subcultures were achieved by not diluting cells at 24 h.  At 48 h  the 
cells were assessed for cytotoxic susceptibility to FVIS. 
$ .% Increase in cell no. is determined by the ratio of the increase in number ofcells during each 
24-h culture period, divided by the number of cells present at the beginning of the 24-h period, 
multiplied by 100%. 
§ Cells cultured in the presence of 5% heat-inactivated NMS. 
dl Cells cultured in the presence of 5% heat-inactivated FVIS. 
¶ % ~lCr release from experimental FLC-745 target cells by a  final 1:20 dilution of FVIS and C. 
The % 51Cr release from cells of the four cultures reacted with C alone was less than 5%. 
** ND,  not done. 
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FIG.  1.  Kinetics of FLV antigenic modulation and reversal of modulation. Cells cultured 
in NMS  (@--O);  cells cultured  in  medium  containing fetal bovine serum  but devoid of 
mouse serum (A--A); cells cultured in FVIS (×--x); cells cultured in FVIS for 48 h  then 
transferred into medium with NMS (O---O); cells cultured in FVIS for 48 h then transferred 
into medium devoid of mouse serum (A--A). E.  V.  GENOVESI,  P.  A.  MARX,  AND  E.  F.  WHEELOCK  525 
cytolysis within  24 h  after transfer  to medium containing  NMS or no mouse 
serum,  indicating  that  antigenic  modulation  was  reversible.  There  was  no 
significant  cytolysis of the cells by C alone.  Cell growth and viability was the 
same  in  each  of the  experimental  cultures  (data  not  shown).  These  results 
indicate that FLC-745 cells cultured in FVIS undergo a  reversible phenotypic 
loss in susceptibility to cytolysis by FVIS. 
Medium from cell cultures containing  FVIS were titrated for residual FLV- 
specific cytotoxic antibody after 24,  48,  and  72 h  of incubation.  For each 24-h 
interval there was a twofold decrease in cytotoxic antibody titer as compared to 
medium  with  FVIS  incubated  in  the  absence  of cells.  It  was  not  possible to 
quantitate  the amount of residual modulating antibody in the cell cultures at 
the  end  of each  24-h period,  because of associated nutrient  depletions  in the 
media.  Therefore,  the  relationship  between the  concentration  of FVIS in the 
culture  medium  and  the  induction  of FLV  antigenic  modulation  was  also 
examined.  FLC-745  cells  were  cultured  in  media  containing  serial  twofold 
dilutions  of FVIS,  ranging  from  1:10  to  1:80.  FLV antigenic  modulation  was 
achieved  at  dilutions  of FVIS up to  1:40.  The  5%  FVIS concentration  in  the 
growth  medium  used in  the  antigenic  modulation  cultures  is thus  a  twofold 
excess concentration  required  for FLV antigenic  modulation.  Furthermore  if 
cytotoxic antibody and modulating antibody decline at the same rate in FLC-745 
cell cultures, then sufficient antibody remained in the cultures at the end of each 
24-h incubation period to achieve antigenic modulation. 
Susceptibility  of FVIS-Modulated FLC-745  Cells to Immune  Cytolysis  by 
Anti-DBA/2 Serum.  The  specificity of FVIS-induced FLV antigenic  modula- 
tion of FLC-745 cells was tested by comparing the susceptibility of modulated 
and unmodulated cells to immune lysis by both FVIS and anti-DBA/2 serum in 
the presence of C. Table II shows that modulated FLC-745 cells were relatively 
resistant to immune lysis by FVIS, but were as susceptible as unmodulated cells 
to lysis by anti-DBA/2 serum.  Modulated FLC-745 cells and unmodulated cells 
were also equally susceptible to lysis by serial twofold dilutions of anti-DBA/2 
serum ranging from 1:80 to 1:640 (data not shown). Thus,  FVIS modulates the 
susceptibility of FLC-745 cells to FLV-specific immune cytolysis without affect- 
ing susceptibility to cytolysis by anti-DBA/2 serum. This observation indicates 
that in the presence of FVIS, FLV cell surface antigens do not co-modulate with 
H-2 d antigens.  The possibility that loss of susceptibility to cytolysis by FVIS is 
due to an anti-complementary factor is also excluded. 
Correlation of Modulation  of FLV Antigens with Capping of FL V-Specific 
Antigen-Antibody Complexes.  The distribution  of FLV-specific antigen-anti- 
body complexes on the surfaces of FLC-745 cells undergoing antigenic modula- 
tion  was determined  by membrane  immunofluorescence.  Samples of cells cul- 
tured in medium containing FVIS or NMS were reacted with fl-GAMg every 6 h 
to detect the presence and position of FLV antigen-antibody complexes during a 
24-h incubation period.  Samples of cells were also tested at 0,  16,  and 24 h  for 
their susceptibility to cytolysis by FVIS. 
At the inception of culture, 91% of the 100% immunofluorescent-positive FLC- 
745 cells displayed FLV antigen-antibody complexes distributed evenly over the 
cell surface  (Fig.  2 A)  and  are  denoted  as rimmed  cells in Table III,  and  9% 
displayed a  patched distribution.  By 6 h  of culture, the percentage of patched 526  ANTIGENIC  MODULATION  OF  FRIEND  ERYTHROLEUKEMIC  CELLS 
TABLE  II 
Susceptibility of Modulated FLC- 745 Cells to tmm une Cytolysis 
By Anti-DBA/2 Serum 
%  5~Cr release 
Mouse serum in assay 
medium* 
Control cells$  Modulated  cells§ 
FVIS  81.8  _-_  1.2  35.7  _+  1.5 
Anti-DBA/2 serum  83.5  -+ 6.9  87.9  -+ 0.7 
Nonell  0.9  _~ 0.3  1.9  -+ 0.1 
* FVIS was used at a  1:20 final dilution with C  and anti-DBA/2 serum 
was used at 1:80 final dilution with C  in the serum cytotoxicity assay. 
$ Control  FLC-745 cells  were  cultured  for  48  h  in  medium  with  NMS 
before use in the serum cytotoxicity assay. 
§ Modulated FLC-745 cells were cultured for 48 h  in medium with FVIS 
before use in the serum cytotoxicity  assay. 
rl None refers to the release of 5~Cr from labeled  target cells incubated 
with guinea pig C  in the absence of cytotoxic serum. 
FIO.  2.  FLC-745 cells were cultured in FVIS, then stained at selected times, during a  24 h 
culture  period  with  fl-GAMg,  to  assess the  distribution  of FLV-immune  complexes.  (A) 
Rimmed fluorescence pattern observed at 0 h. (B) Patched fluorescence pattern observed at 
6 h.  (C) Capped fluorescence pattern observed at 18 h.  (D) A  cell negative for fluorescence 
observed at 24 h.  (×  5,000). E.  V.  GENOVESI,  P.  A.  MARX,  AND  E.  F.  WHEELOCK  527 
TABLE  III 
Distribution of FLV Antigen-Antibody Complexes on the Surface of FLC-745 Cells 
Cultured in Dormant FVIS 
Distribution of fluorescence 
on cell surface 
% Cells with FLV antigen-antibody complexes in cultures contain- 
ing dormant FVIS 
Time in culture  (h)* 
05  6  12  16  18  24 
Positive  100  99  87  ND§  70  35 
Rimmed  91  30  10  ND  2  0 
Patched  9  54  38  ND  9  4 
Capped  0  15  39  ND  59  31 
Negative  0  1  13  ND  30  65 
Mouse serum  in culture  me- 
dium  % s~Cr release by dormant FVISII 
FVIS  68.9 -  1.0  ND  ND  51.9 + 2.9  ND  35,7 _+ 1.5 
NMS  67.3 -+ 2.0  ND  ND  79.9 -  0.7  ND  81.8 _+ 1.2 
* FLC-745 cells were cultured  in medium with FVIS or NMS. At the indicated time points, the 
cells  were  washed  and  stained  in  suspension  with  fluorescein-conjugated goat  anti-mouse 
gamma globulin. 
At the  0 h  time  point  FLC-745 cells  were  reacted  with  FVIS,  washed,  then  stained  with 
fluorescein-conjugated goat anti-mouse gamma globulin. 
II At 0, 16, and 24 h, samples of cells, from the same cultures used for fluorescence staining,  were 
labeled with 5~Cr and tested for their cytotoxic susceptibility to a 1:20 final dilution of FVIS and 
C. The percent s~Cr release from the cells from both cultures reacted with C alone was less then 
5%. 
§ ND, not done. 
cells had increased from 9 to 54% and then progressively declined to 4% at 24 h. 
The percentage of cells  displaying unipolar  caps increased,  reaching a  maxi- 
mum of 59% after 18 h  of incubation. During the 24-h culture period in medium 
containing FVIS, the percentage of cells that were negative for FLV antigen- 
antibody complexes progressively increased from 0 to 65%.  The percentage of 
cells with rimmed fluorescence progressively declined from 91 to 0% during the 
24-h culture period.  None of the NMS-cultured cells displayed immunofluores- 
cence (data not shown), indicating that NMS does not have 7S gamma globulin 
specific for FLC-745 cell surface antigens. The data indicate that during culture 
in  FVIS,  murine  7S  gamma  globulin  attaches  to  FLV  antigen  on  the  cell 
membrane,  forming antigen-antibody complexes which are redistributed  over 
the cell surface in the following progression: rimmed, patched, capped, and loss 
of FLV-specific  immune  complexes.  These  immunofluorescence patterns  are 
shown in Fig.  2. 
During the first 18 h  of culture in FVIS, the FLC-745 cells became relatively 
resistant to cytolysis by FVIS, coincident with the appearance of a  maximum 
percentage  of cells  displaying  capping.  At  24  h,  when  this  experiment  was 
terminated,  96%  of the cells were  either capped or immune complex negative 
and there was a  further increase in resistance to cytolysis by FVIS; maximum 
levels  of resistance  usually occur between 24 and 48 h  of culture  (see Fig.  1). 
These results indicate a temporal relationship between redistribution and loss of 
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by FVIS. The maximum resistance of cells to lysis by FVIS and C is preceded by 
the appearance of a  maximum percentage of cells with capped FLV antigen- 
antibody complexes. 
Expression  of  FLV  Antigens  on  the  Surface  of  Modulated  FLC-745 
Cells.  Using the membrane immunofluorescence  assay, control and modulated 
FLC-745 cells were examined for FLV antigens, to determine whether antigenic 
modulation was  associated with  suppressed  expression of the  FLV genome. 
FLC-745 cells were cultured in medium containing FVIS for 72  h  to  achieve 
modulation, and in medium containing NMS as a control. Samples of cells from 
the cultures at 0, 24, 48, and 72 h were reacted with FVIS followed by fl-GAMg. 
This procedure should result in the fluorescent labeling of  all cells whose surface 
membranes contain either uncomplexed or  antibody-complexed FLV  antigen 
before the staining procedure. 
As shown in Table IV, 26% of the modulated cells at 48 h were devoid of both 
immune complexes and free FLV cell membrane antigens. This redistribution of 
surface antigens also correlated with decreased susceptibility of FLC-745 cells to 
lysis by  FVIS  and  C.  These  results  suggest  that  FVIS  does  suppress  FLV 
antigen expression at the cell surface. However, possible spatial and steric cell 
surface alterations associated with capping may have interfered with the stain- 
ing of immune complexes on modulated cells by fl-GAMg. 
Discussion 
In this report we have demonstrated that FLV cell surface antigens on FLV 
erythroleukemic cells are modulated after in vitro cultivation in medium con- 
taining serum from mice with dormant FLV infections. Modulated FLV-ery- 
throleukemic cells were not altered in their rate of division and expressed less 
FLV antigen on the cell surface as demonstrated by membrane immunofluores- 
cent microscopy and their relative resistance to FLV-immune cytolysis. Modu- 
lated cells transferred to medium containing NMS re-expressed their FLV cell 
surface antigens within 24 h. 
A decrease in the amount of FLV cell surface antigens could either be caused 
by inhibition of genomic expression or be a manifestation of antigenic modula- 
tion whose  effects are  confined to  the  cell  membrane.  Data  from studies of 
surface antigens on cells cultured in medium containing specific immune serum 
must be viewed cautiously since the amount of surface antigen present has been 
shown to be determined by the rates of antigen production, their complexing 
with specific antibody, and shedding or internalization of the complexes (35, 36, 
42). If FLV antigen is produced at a  relatively slow rate, then removal of the 
antigen from the cell surface during modulation may lead to a prolonged period 
in which the surface is devoid of detectable antigen. An alternative mechanism 
is that expression of the FLV genome is itself inhibited. The above mentioned 
dynamics of appearance,  accumulation, and shedding of FLV antigens on the 
cell surface,  in the presence of FVIS,  prevents a  clear interpretation of data 
obtained from cell surface studies. Suppression of  the FLV genome in modulated 
cells can best be determined by evaluation of the synthesis of virion polypep- 
tides. Such studies will be the subject of a future communication. 
Identification of the modulating antibody in the FLV system is currently in E.  V.  GENOVESI,  P.  A.  MARX~  AND  E.  F.  WHEELOCK 
TABLE IV 
Expression  of FLV Antigens on the Surfaces  of Modulated FLC-745 Cells 
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% Cells with FLV-specific immunofluorescence* 
Mouse serum in 
culture  medium  Time in culture  (h) 
0  24  48  72 
FVIS  100 (0)$  85 (15)  74 (26)  77 (23) 
NMS  100 (0)  97 (3)  99 (1)  98 (2) 
% 5~Cr release by dormant FVIS§ 
FVIS  80.6 + 2.0  36.6 +- 0.0  23.3 -+ 0.5  19.0 + 0.4 
NMS  95.1 ~ 4.5  78.5 -+ 1.1  66.8 -+ 0.1  58.7 _+ 0.5 
* FLC-745 cells were  cultured  in  medium  with  FVIS or NMS. At the indicated  time  points, 
samples of cells were reacted  with  FVIS and  stained  with  fluorescein-conjugated goat anti- 
mouse gamma globulin to determine the percentage of  cells displaying FLV-specific  immunoflu- 
orescence. 
* The number in the parentheses  indicates the percentage of cells in culture which were negative 
for FLV-specific immunofluorescence. 
§ At the time  points indicated,  samples of cells, from the same cultures  used for fluorescence 
staining,  were labeled  with  51Cr and  tested  for their  cytotoxic susceptibility  to a  1:20 final 
dilution of FVIS and C. The % 51Cr release from the cells from both cultures reacted with C alone 
was less than 5%. 
progress.  Analysis of dormant  FLV-immune serum  has  revealed  antibody to 
gp69/71, gp43, p15, and p12. ~ Of special note is that serum from overtly leukemic 
mice contain the same antibody specificities except for an absence of antibody to 
p12.  p12 may be the antigen which serves as the common target for antibody- 
mediated C-dependent lysis on Friend,  Rauscher,  and Moloney leukemic cells 
(R.  Steeves,  personal communication) and may have been the  modulated cell 
surface antigen in the experiments described here. Although the precise role of 
antibody to p12 in dormant FLV infections remains to be determined, a correla- 
tion exists between FLV dormancy and the presence of p12 antibody, and pro- 
duction  of this  antibody  may determine  whether  a  statolon-treated  FLV-in- 
fected mouse will develop dormant or overt FLV erythroleukemia. 
Our  experiments  have  revealed  that  FLC-745  cells  in  logarithmic  growth 
phase cultures are more susceptible to FLV-immune cytolysis in the absence of 
FVIS and when cultured in the presence of FVIS, underwent antigenic modula- 
tion to a  greater extent than cells in a  resting state.  FLV erythroleukemic cells 
have been shown to cease production of virus on entering the Go or resting state 
(43).  The decreased production of virus antigens in resting phase cells may be 
the cause of the decreased susceptibility to cytolysis. However, the reasons for 
the  decreased  ability  of cells  in  Go to  undergo  antigenic  modulation  are  un- 
known and the problem should be further studied. 
Modulation of FLV cell surface antigens was produced by medium containing 
a constant excess of cytotoxic antibody. Although between 70 and 87% of cells at 
16  h  in  modulated  cultures  contained  antigen-antibody  complexes  on  their 
Marx, P. A., and E. F. Wheelock. 1977. Antibody to Friend leukemia virus polypeptide p12: 
basis for establishment  and maintenance  of dormant erythroleukemia.  Manuscript in prepara- 
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surface (Table III), they were not lysed by C  alone.  The inability of C to lyse 
modulated FLC-745 cells despite the detection of immunoglobulin on these cells 
by immunofluorescence, suggests that the amount of antibody bound to the cells 
was below that required for C fixation and cell lysis (44). It is also possible that 
cells with  capped antigen-antibody  complexes were either  unable  to fix C  or 
were not lysed due to cell membrane  configurational  changes associated with 
antigenic modulation. 
FLV antigenic modulation, as measured by the increased resistance of modu- 
lated cells to FLV-specific antibody-mediated lysis, was temporally associated 
with  cap  formation  on  the  surface  of FLC-745  cells.  The  internalization  or 
shedding of immune complexes (45, 46) from the cell surface may reduce the cell 
surface  antigen  density,  and  increase  the  resistance  of modulated  cells  to 
antibody-mediated  C-dependent  cytolysis.  Similar  temporal  correlations  be- 
tween  modulation  and  capping  were observed for  MuMTV  antigens  (26).  In 
contrast to the above systems, measles virus antigenic modulation was preceded 
by capping which was associated with a  transient  increase in susceptibility to 
immune  cytolysis (30).  However,  studies  of modulation  of TL  antigens  have 
suggested that capping is not a requisite for antigenic modulation (34, 36). The 
mechanisms involved in antigenic modulation and any differences in association 
with capping may reflect the intrinsic metabolism and physiology of the various 
cell systems studied. 
Antibody-induced capping and modulation of a specific antigen may affect the 
expression and distribution of other cell surface antigens (47). In this communi- 
cation, evidence was presented showing that the modulation of FLV antigens on 
FLC-745 cells does not affect the cytotoxic susceptibility of these cells to anti- 
allotype  serum.  No  effect on  the  expression  of cell  surface  alloantigens  and 
differentiation  antigens  was  observed on  GCSA  and  MuMTV  antigen-modu- 
lated cells (19, 26). However, the modulation of TL antigens was accompanied by 
an  increased  expression  of H-2D  haplotype  antigens  (15).  Antibody-induced 
capping  of FLV cell  surface  antigens  on BALB/c erythroblasts  depressed the 
expression of H-2D antigens.  This observation suggests that  FLV cell surface 
antigens  are  physically associated with  H-2D antigens  (R.  Steeves, personal 
communication).  However, our studies were confined to the entire H-2 antigen 
complex which did not modulate with FLV cell surface antigens. 
Antibody  may  play  a  role  in  persistent  and  latent  viral  diseases through 
antigenic modulation.  Measles virus persistance in subacute sclerosing panen- 
cephalitis  (30)  and  herpes  simplex  virus  latency  (48)  may  be  achieved  by 
antibody-induced modulation of viral antigens  at the cell surface.  The in vivo 
modulation of Gross leukemia virus antigens in rats (20), SV-40 virus antigens 
in  hamsters  (22),  and  the  in  vitro  modulation  of EBV  antigens  in  Burkitt 
lymphoma cells by human  convalescent EBV serum  (23) has been associated 
with suppressed expression of viral genomes in transformed cells. In contrast, 
GCSA expression on murine lymphomas was suppressed after passage through 
immune mice without any effect on the expression of C-type particles and other 
associated virion antigens (19). These experiments are analogous to ours in one 
important  respect:  modulation  was  produced  with  serum  obtained  from  the 
infected or tumor-bearing  hosts.  Such serum  would be expected to contain  a E.  V.  GENOVESI,  P.  A.  MARX,  AND  E.  F.  WHEELOCK  531 
complete  range  of antibodies  directed  against  virion  and  virus-induced  cell 
membrane  antigens  and,  therefore,  modulating  and  tumor-suppressive  anti- 
bodies are more likely to be present than in a host immunized with single anti- 
gens.  Prophylactic  immunization  of mice  and  passive  transfer  of antibodies 
against endogenous virus particles were reported to prevent spontaneous tumor 
emergence and endogenous virus expression  (49,  50).  The role of humoral im- 
munity in these tumor models still needs to be delineated; however, antibody 
may act to regulate virogene and oncogene expression at the cellular level by a 
mechanism similar to antigenic modulation. Thus, antigenic modulation of FLV 
erythroleukemic cells might inhibit FLV genome expression in vivo and be re- 
sponsible for the tumor dormant state. 
Since serum from mice containing dormant FLV-infected cells produced mod- 
ulating effects on FLV-transformed cells in vitro, the role of antigenic modula- 
tion in tumor suppression and emergence in vivo must be re-evaluated, at least 
in the exogenous viral  leukemias.  Antigenic  modulation  has been previously 
demonstrated to be a  mechanism by which tumor cells shed their cell surface 
tumor-associated antigens,  and thereby escape from the immune response and 
grow out to  overt neoplasia.  However, in  the  dormant  FLV-infected  mouse, 
FLV-infected cells persist for many months without producing neoplasia in the 
presence of antibody that has antigenic-modulating  properties in vitro.  Our in 
vitro studies indicate that the rate oferythroleukemia cell growth is not altered 
during the modulation of FLV cell surface antigens.  However, preliminary  in 
vivo experiments have revealed that dormant FLV-infected mice suppress out- 
growth of small numbers of FLC-745 cells,  and the FLC-745 cells in Millipore 
diffusion chambers in dormant FLV-infected mice are inhibited in their rate of 
division as compared with FLC-745 cells in chambers in normal mice. Therefore 
the  absence  of C5  and  ADCC  reactions  in  the  DBA/2  mouse,  coupled  with 
studies in progress and those reported here, suggest that FLV antibodies act in 
vivo in conjunction with other humoral factors to suppress division of FLC-745 
cells, possibly through antigenic modulation. 
Summary 
Friend  leukemia  virus  (FLV)  erythroleukemic  cells  cultured  in  medium 
containing FLV-immune serum from dormant FLV-infected mice undergo mod- 
ulation  of FLV cell  surface  antigens.  Modulation  was  determined  by an  in- 
creased resistance to FLV antibody-mediated complement-dependent lysis and 
was associated temporally with the capping of FLV-immune complexes at the 
cell  surface.  Modulated  cells  regained  their  susceptibility to  FLV  antibody- 
mediated complement-dependent lysis when transferred to medium containing 
normal mouse serum.  After 48 h  of culture in FLV-immune serum, 26% of the 
FLV erythroleukemic cells were devoid of FLV cell surface antigens as demon- 
strated  by immunofluorescence.  Antigenic  modulation  occurred  to  a  greater 
extent in cells maintained  in logarithmic growth than in cells in Go or resting 
phase.  FLV-antigenic  modulation  is  discussed  as  a  possible  mechanism  by 
which  antibody  induces  and  maintains  FLV-transformed  cells  in  a  dormant 
state. 532  ANTIGENIC  MODULATION  OF  FRIEND  ERYTHROLEUKEMIC  CELLS 
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